Daisuke Kaya

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease

Kazuki Tahara, Takemi Akahane, Tadashi Namisaki et al. · JGH Open · 2019 · 47 citations · Full text

Medicine, Endocrinology, Pathology +16

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

Kosuke Kaji, Soichiro Saikawa, Hiroaki Takaya et al. · Antibiotics · 2020 · 42 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis

Yukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya et al. · International Journal of Molecular Sciences · 2020 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato et al. · International Journal of Molecular Sciences · 2020 · 28 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats

Daisuke Kaya, Kosuke Kaji, Yuki Tsuji et al. · Cells · 2019 · 27 citations · Full text

Medicine, Endocrinology, Pharmacology +17